Filter by
Bioequivalence Comparison of Two Formulations of Fixed-Dose Combination Glime…
Glimepiride/metformin (2/500 mg) is an oral antihyperglycemic agent for the treatment of type 2 diabetes. A generic glimepiride/metformin (2/500 mg) fixed-dose combination (FDC) tablet was developed recently. This study was designed to collect data for submission to Korean regulatory authorities to allow the marketing of the test formulation. We evaluated the comparative bioavailability and to…
- Edition
- -
- ISBN/ISSN
- -
- Collation
- -
- Series Title
- -
- Call Number
- -
Glimepiride
Glimepiride is used as monotherapy as an adjunct to diet and exercise for the management of type 2 (noninsulindependent) diabetes mellitus (NIDDM) in patients whose hyperglycemia cannot be controlled by diet and exercise alone.1,54 Sulfonylureas, including glimepiride, also may be used in combination with one or more other oral antidiabetic agents or insulin as an adjunct to diet and exercise …
- Edition
- -
- ISBN/ISSN
- -
- Collation
- -
- Series Title
- -
- Call Number
- -
Glimepiride : A Review of its Use in the Management of Type 2 Diabetes Mellitus
Glimepiride is a sulphonylurea agent that stimulates insulin release from pancreatic b-cells and may act via extrapancreatic mechanisms. It is administered once daily to patients with type 2 (non–insulin-dependent) diabetes mellitus in whom glycaemia is not controlled by diet and exercise alone, and may be combined with insulin in patients with secondary sulphonylurea failure
- Edition
- -
- ISBN/ISSN
- -
- Collation
- -
- Series Title
- -
- Call Number
- -
Clinical review of glimperide
This article reviews the pharmacological and clinical aspects of glimepiride, the latest second-generation sulfonylurea for treatment of type 2 diabetes mellitus (DM)
- Edition
- -
- ISBN/ISSN
- -
- Collation
- -
- Series Title
- -
- Call Number
- -
New Trends in the Development of Oral Antidiabetic Drugs
A large number of oral antidiabetic agents are available today. This article provides a short review of the pharmacology and some clinical aspects of various oral antidiabetic drugs. It focuses mainly on the newest developing drugs (therapy of the near future) and on the most commonly used older groups for the common approach of everyday practice (sulphonyureas)
- Edition
- -
- ISBN/ISSN
- -
- Collation
- -
- Series Title
- -
- Call Number
- -
The pathophysiologic basis of efficacy and clinical experience with the new o…
Type 2 diabetes results from the abnormal resistance of peripheral tissues to insulin and from the progressive insulin secretory failure of the pancreatic b-cells. Treatment of type 2 diabetes has greatly improved due to the availability of new classes of oral antidiabetic drugs (OADs) and new insulin analogs. Three types of oral medications exert their antidiabetic action without directly stim…
- Edition
- -
- ISBN/ISSN
- -
- Collation
- -
- Series Title
- -
- Call Number
- -
The Effect of Glimepiride on Glycemic Control and Fasting Insulin Levels
Glimepiride is a new once-daily sulfonylurea. Animal studies have shown that it lowers blood glucose through extrapancreatic process. The aim of our study is to observe the effect of glimepiride on glycemic control, body weight change and insulin levels during fasting. Thirty two Type 2 diabetic patients, whose blood glucose levels cannot be controlled adequately with diet and exercise alone,…
- Edition
- -
- ISBN/ISSN
- -
- Collation
- -
- Series Title
- -
- Call Number
- -
Plasma Adiponectin Plays an Important Role in Improving Insulin Resistance Wi…
We investigated the effect of glimepiride, a third-generation sulfonylurea hypoglycemic agent, on insulin resistance in elderly patients with type 2 diabetes, in connection with plasma adiponectin and 8-epi-prostagrandin F2 (8-epi-PGF2), an oxidative stress marker.
- Edition
- -
- ISBN/ISSN
- -
- Collation
- -
- Series Title
- -
- Call Number
- -
Effects of Febuxostat Versus Allopurinol and Placebo in Reducing Serum Urate …
To compare the urate-lowering efficacy and safety of febuxostat, allopurinol, and placebo in a large group of subjects with hyperuricemia and gout, including persons with impaired renal function
- Edition
- -
- ISBN/ISSN
- -
- Collation
- -
- Series Title
- -
- Call Number
- -
Clinical Efficacy and Safety of Successful Longterm Urate Lowering with Febux…
After 1 month initial treatment, > 80% of subjects receiving either febuxostat dose, but only 46% of subjects receiving allopurinol, achieved SUA < 6.0 mg/dl. After ULT reassignment, > 80% of all remaining subjects maintained the primary efficacy endpoint of SUA < 6.0 mg/dl at each visit. More subjects initially randomized to allopurinol required ULT reassignment to achieve SUA < 6.0 mg/dl com…
- Edition
- -
- ISBN/ISSN
- -
- Collation
- -
- Series Title
- -
- Call Number
- -
Computer Science, Information & General Works 
Philosophy & Psychology 
Religion 
Social Sciences 
Language 
Pure Science 
Applied Sciences 
Art & Recreation 
Literature 
History & Geography